Schellenberg Wittmer advised Swisscanto, the growth fund of Zürcher Kantonalbank's asset management division, as lead investor in a USD 25 million financing round for Piomic Medical, an ETH Zurich spin-off developing regenerative medtech therapies.
Tags :Zürcher Kantonalbank
Homburger acted as counsel to Zürcher Kantonalbank on the issuance of EUR 500 million 3.080 per cent Fixed Rate Bonds due May 2029, with BNP Paribas, Commerzbank, UBS AG London Branch, and Zürcher Kantonalbank serving as
